SUCCESS RATES OF
CAR-T THERAPY
Real outcome data across cancer types β what the numbers measure, what they don't, and how to contextualise them for your specific situation.
The Numbers in Context
CAR-T success rates are measured by ORR, CR, PFS, and OS β different metrics that don't substitute for each other. The patients in these trials had failed 2-6+ prior lines. A 40% CR in this population is a very different thing from 40% in newly diagnosed patients.
βThese numbers describe populations, not individuals. But for a population that had exhausted options, they represent a genuine shift.β
CAR-T Response Rates by Cancer Type
Complete Response Rates
Long-Term Durability Data
- 42.6%Axi-cel DLBCL patients in remission at 5 years
- 70-90%CR rate in paediatric relapsed/refractory B-ALL
- 97.9%ORR with Carvykti in heavily pre-treated myeloma
Frequently Asked Questions
About Success Rates
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Understand Success Rates for Your Specific Case?
A specialist consultation contextualises published data for your cancer subtype, treatment history, and the product being proposed.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.